With the objective of improving the early detection, treatment and survival of cancer patients, KAPS Biotech is focused on the development of new cancer biomarkers. Involving practioners longtime focused on improving cancer outcomes, principals of the firm are structured around bringing the full in-use condition a unique panel of biomarker(s) for the early detection of PCa that can inform treatment decision making and improve monitoring men with PCa. The firm's previous work has shown that the known drawbacks of currently available PSA test can be overcome by their panel of biomarkers that are able to differentiate benign prostate and PCa with greater specificity and identify men who have high risk (aggressive) PCa.